ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs148.1 M121.8 M124.8 M106.8 M103 M100.5 M435.1 MRecherche et développement———————Résultat d'exploitation-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-3.4 M-355.9 MTotal des produits hors exploitation2.5 M-5.6 M-17.1 M2.5 M1.1 M10.2 M-3.3 MCharges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts-3.7 M-5.6 M-19.9 M-2.6 M1.1 M9.7 M-11.7 MRevenus/dépenses exceptionnels6.2 M02.8 M5.1 M0500 K8.4 MRésultat avant impôts-74.9 M-548 M-370.7 M-28.7 M-35.6 M-12.3 M-447.3 MPart des actionnaires dans le résultat———————Impôts-1 M14.9 M4.2 M-12.8 M-3.1 M11.3 M-400 KIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts-4.6 M-300 K-2 M100 K-2.3 M-400 K-4.6 MRésultat net avant activités abandonnées-73.9 M-562.9 M-374.9 M-15.9 M-32.5 M-23.6 M-446.9 MActivités abandonnées12.7 M0000——Résultat net-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-23.6 M-446.9 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-23.6 M-446.9 MBénéfice par action de base (BPA de base)-0.68-6.25-4.14-0.17-0.25-0.25-4.81Bénéfice par action dilué (BPA dilué)-0.68-6.25-4.14-0.17-0.25-0.25-4.81Nombre moyen d'actions de base en circulation89.5 M————93.6 M—Nombre d'actions en circulation après dilution89.5 M————93.6 M—EBITDA-34.8 M-500.6 M-310.7 M11 M5.7 M16.4 M-277.6 MEBIT-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-3.4 M-355.9 MCoût des ventes556.1 M534.8 M576.8 M578.6 M529.4 M512.9 M2.2 BAutres coûts des ventes556.1 M534.8 M576.8 M578.6 M529.4 M512.9 M2.2 BAmortissements (flux de trésorerie)20.8 M19.5 M19.6 M19.6 M19.3 M19.8 M78.3 M
Fortrea Holdings Inc. - Common Stock
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.